References
- Bhartia B., Ward J., Guthrie J. A., Robinson P. J. Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. Am J Roentgenol 2003; 180: 577–84
- El-Serag H. B., Mason A. C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–50
- Hamm B., Staks T., Muhler A., Bollow M., Taupitz M., Frenzel T., et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785–92
- Hori M., Murakami T., Kim T., Tsuda K., Takahashi S., Okada A., et al. Detection of hypervascular hepatocellular carcinoma: comparison of SPIO-enhanced MRI with dynamic helical CT. J Comput Assist Tomogr 2002; 26: 701–10
- Jung G., Cohnen M., Poll L. W., Koch J. A., Mödder U. Value of CT and MRI in the diagnosis of malignant liver tumors. Onkologe 2003; 9: 263–71
- Kang B. K., Lim J. H., Kim S. H., Choi D., Lim H. K., Lee W. J., et al. Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology 2003; 226: 79–85
- Kim S. K., Kim S. H., Lee W. J., Kim H., Seo J. W., Choi D., et al. Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging. Am J Roentgenol 2002; 179: 741–50
- Matsuo M., Kanematsu M., Itoh K., Ito K., Maetani Y., Kondo H., et al. Detection of malignant hepatic tumors: comparison of gadolinium- and ferumoxide-enhanced MR imaging. Am J Roentgenol 2001; 177: 637–43
- Mori K., Scheidler J., Helmberger T., Holzknecht N., Schauer R., Schirren C. A., et al. Detection of malignant hepatic lesions before orthotopic liver transplantation: accuracy of ferumoxides-enhanced MR imaging. Am J Roentgenol 2002; 179: 1045–51
- Okuda K., Ohtsuki T., Obata H., Tomimatsu M., Okazaki N., Hasegawa H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918–28
- Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 2002; 17: 401–5
- Pauleit D., Textor J., Bachmann R., Conrad R., Flacke S., Layer G., et al. Hepatocellular carcinoma: detection with gadolinium- and ferumoxide-enhanced MR imaging of the liver. Radiology 2002; 222: 73–80
- Schuhmann-Giampieri G., Schmitt-Willich H., Press W. R., Negishi C., Weinmann H. J., Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183: 59–64
- Tang Y., Yamashita Y., Arakawa A., Namimoto T., Mitsuzaki K., Abe Y., et al. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging. Am J Roentgenol 1999; 172: 1547–54
- Vogl T. J., Kummel S., Hammerstingl R., Schellenbeck M., Schumacher G., Balzer T., et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200: 59–67
- Ward J., Guthrie J. A., Scott D. J., Atchley J., Wilson D., Davies M. H., et al. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 2000; 216: 154–62
- Ward J., Robinson P. J. How to detect hepatocellular carcinoma in cirrhosis. Eur Radiol 2002; 12: 2258–72